The AstraZeneca Enhertu DESTINY-Lung04 Trial has officially reported Phase III clinical trial results, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously untreated HER2-mutant non-small cell lung cancer (NSCLC). In this global, randomized, open-label trial, fam-trastuzumab deruxtecan-nxki (Enhertu), an antibody-drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo, achieved a median PFS of 14.3 months compared to 8.3 months for the standard-of-care chemoimmunotherapy control arm. As documented on the AstraZeneca Press Release Hub, these findings mark DESTINY-Lung04 as the first Phase III trial to establish superior efficacy for a HER2-directed targeted agent over standard first-line treatment in this patient population.
The AstraZeneca Enhertu DESTINY-Lung04 Trial enrolled 454 patients diagnosed with unresectable, locally advanced or metastatic non-squamous NSCLC harboring activating HER2 exon 19 or exon 20 mutations. Participants were randomized in a 1:1 ratio to receive either Enhertu monotherapy at a dose of 5.4 mg/kg intravenously every three weeks or the standard-of-care regimen consisting of pembrolizumab in combination with investigator-choice platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed for up to four cycles followed by pemetrexed maintenance therapy. Randomization across global study centers was stratified according to patient smoking history and prior presence or history of brain metastases to ensure balanced baseline characteristics.
Evaluation of the primary endpoint, blinded independent central review (BICR)-assessed progression-free survival, demonstrated that Enhertu reduced the risk of disease progression or death by 37% (hazard ratio [HR] = 0.63; 95% CI: 0.50–0.79; p < 0.0001) relative to standard chemoimmunotherapy. The 6-month extension in median PFS represents a major milestone for frontline lung cancer management, where HER2 mutations, occurring in roughly 2% to 4% of non-squamous NSCLC cases, historically carry poor long-term clinical prognoses.
Efficacy Outcomes in the AstraZeneca Enhertu DESTINY-Lung04 Trial
Secondary efficacy parameters assessed during the AstraZeneca Enhertu DESTINY-Lung04 Trial further validated the clinical profile of the targeted antibody-drug conjugate. The confirmed objective response rate (ORR) achieved with Enhertu reached 70.0% compared to 44.5% in the chemoimmunotherapy comparative arm. Furthermore, Enhertu-induced responses were more durable, with a median duration of response (DOR) of 13.4 months versus 9.7 months for patients receiving standard pembrolizumab plus chemotherapy. At the time of data cut-off (June 9, 2026), overall survival (OS) data were 46.9% mature, without formal hypothesis testing performed, impacted in part by post-progression therapy patterns across study arms.
Subgroup analyses from the trial revealed consistent progression-free survival benefits across key clinical demographics and molecular subsets. Patients evaluated within the AstraZeneca Enhertu DESTINY-Lung04 Trial demonstrated hazard ratio reductions favoring Enhertu regardless of baseline liver metastases status, central nervous system/brain metastases, or whether the underlying mutation was located on HER2 exon 19 or exon 20. These findings reinforce the therapeutic potential of moving T-DXd from second-line management directly into the frontline setting for treatment-naive patients.
Safety evaluation within the trial confirmed that the safety profile of Enhertu (5.4 mg/kg) remained generally consistent with previous clinical trials, with no new safety signals identified. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 34.1% of patients receiving Enhertu. Interstitial lung disease (ILD) or pneumonitis, a recognized adverse event associated with HER2-targeted ADCs, was reported in 20.8% of patients in the Enhertu arm (Grade 1: 3.1%, Grade 2: 13.3%, Grade 3: 2.2%, Grade 4: 0.4%, and Grade 5: 1.8%, representing 4 fatal cases).
Safety Data and Clinical Implications of the AstraZeneca Enhertu DESTINY-Lung04 Trial
The comprehensive data reported from the AstraZeneca Enhertu DESTINY-Lung04 Trial highlight a potential shift in therapeutic strategy for advanced non-squamous lung cancer harboring HER2 alterations. By outperforming the standard-of-care combination of anti-PD-1 immunotherapy and platinum-doublet chemotherapy, Enhertu provides a compelling rationale for early molecular screening and targeted first-line administration. Detailed protocol specifications and clinical endpoints are cataloged directly on ClinicalTrials.gov (NCT05048797).
In summary, completing the primary analysis of the AstraZeneca Enhertu DESTINY-Lung04 Trial establishes a new benchmark for HER2-directed medicine in frontline thoracic oncology. As regulatory filings progress based on these Phase III findings, clinicians and regulatory bodies continue to evaluate the clinical impact of frontline T-DXd monotherapy versus sequential treatment strategies in advanced HER2-mutant non-small cell lung cancer.
| Clinical Parameter / Trial Metric | AstraZeneca Enhertu Arm (T-DXd 5.4 mg/kg) | Standard of Care Arm (Pembrolizumab + Chemo) | Statistical Result / Hazard Ratio |
| Study Population | 227 Patients | 227 Patients | Total N = 454 (Randomized 1:1) |
| Median Follow-up Duration | 21.6 Months | 20.4 Months | Data Cut-off: June 9, 2026 |
| Median Progression-Free Survival (BICR) | 14.3 Months (95% CI: 12.4–16.5) | 8.3 Months (95% CI: 7.0–9.9) | HR = 0.63 (95% CI: 0.50–0.79; p < 0.0001) |
| PFS Risk Reduction | 37% Reduction in Progression/Death | Baseline Comparator | p < 0.0001 |
| Objective Response Rate (ORR) | 70.0% | 44.5% | Confirmed Secondary Endpoint |
| Median Duration of Response (DOR) | 13.4 Months | 9.7 Months | Secondary Endpoint |
| Grade ≥3 Treatment-Related Adverse Events | 34.1% | Protocol Specified | Consistent with Known Safety Profile |
| Interstitial Lung Disease (ILD) / Pneumonitis | 20.8% Total (G1: 3.1%, G2: 13.3%, G3: 2.2%, G4: 0.4%, G5: 1.8%) | N/A | 4 Grade 5 Events (1.8%) |
